- Trials with a EudraCT protocol (371)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1,733)
371 result(s) found for: Ear.
Displaying page 7 of 19.
EudraCT Number: 2015-004012-37 | Sponsor Protocol Number: HOM1-2015 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:Ordination Dr. Hommer | |||||||||||||
Full Title: An open, non-randomized study on the effect of changing from preserved prostaglandin formulations to preservative free tafluprost (Saflutan® Augentropfen) in patients with ocular hypertension or pr... | |||||||||||||
Medical condition: Glaucoma / Ocular Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024046-29 | Sponsor Protocol Number: GEP 11/1010 | Start Date*: 2013-05-28 | |||||||||||
Sponsor Name:FNCLCC | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004274-10 | Sponsor Protocol Number: Etoric-TE-1 | Start Date*: 2008-06-16 | |||||||||||
Sponsor Name:Freistaat Bayern | |||||||||||||
Full Title: Analgesic efficacy and safety of etoricoxib in ear nose throat surgery | |||||||||||||
Medical condition: The aim of this study is to test the analgesic efficacy and safety of etoricoxib (90 mg or 120 mg qd. perioperatively) for post-operative pain relief in tonsillectomy patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022899-32 | Sponsor Protocol Number: TH0918 | Start Date*: 2011-01-19 | |||||||||||
Sponsor Name:Celerion | |||||||||||||
Full Title: An open label, randomised, single dose, 5 way cross over study to compare the rate and extent of absorption of a 8.75mg Flurbiprofen lozenge with flavour and excipient base variants of a 8.75mg Fl... | |||||||||||||
Medical condition: Sore throat | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002865-40 | Sponsor Protocol Number: BIODYMF | Start Date*: 2015-12-08 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Open label two treatment half-side comparative study to analyse difference in nasal bioavailability between MP29-02 and fluticasone propionate. | ||
Medical condition: Subjects who need to undergo septoplasty, septorhinoplasty or functional endoscopic sinus surgery unrelated to this study. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005623-16 | Sponsor Protocol Number: OY122013 | Start Date*: 2014-03-20 | |||||||||||
Sponsor Name:Minna Honkila | |||||||||||||
Full Title: ANTIBIOTICS VERSUS PLACEBO FOR ACUTE BACTERIAL CONJUNCTIVITIS IN CHILDREN: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL | |||||||||||||
Medical condition: Acute conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005308-12 | Sponsor Protocol Number: 1111 | Start Date*: 2018-09-07 | |||||||||||
Sponsor Name:Region Sjælland, Slagelse Hospital | |||||||||||||
Full Title: Treatment of MRSA throat carriage with mupirocin irrigation | |||||||||||||
Medical condition: Patientents being MRSA positive for a minimum of 6 months and concluded at least one konventional topical treatments unsuccessfully | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004021-71 | Sponsor Protocol Number: NL.78693.041.21 | Start Date*: 2021-10-13 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: COrticosteroids for COVID-19 induced loss of Smell – COCOS trial | ||
Medical condition: Loss of smell after COVID-19 infection, persisting after 4 weeks | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005527-36 | Sponsor Protocol Number: HEP1-CoV | Start Date*: 2022-08-10 |
Sponsor Name:Gesellschaft für Zelltherapie mbH | ||
Full Title: Human Ezrin Peptide 1 (HEP1) as a therapeutic agent for SARS-CoV-2 (COVID 19) positive patients - a randomized controlled clinical trial | ||
Medical condition: Patients admitted to hospital with a SARS CoV 2 infection with fever and other COVID relevant symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001425-48 | Sponsor Protocol Number: BLUEBERRY | Start Date*: 2021-07-07 |
Sponsor Name:Division of Anaesthesiology - Department of Acute Medicine - Geneva Children's Hospital, University Hospitals of Geneva | ||
Full Title: Dexamethasone and postoperative bleeding following tonsillectomy in children | ||
Medical condition: Tonsillectomy/tonsillotomy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-003119-50 | Sponsor Protocol Number: HYKSKIPU2011-1 | Start Date*: 2011-08-17 | |||||||||||
Sponsor Name:Vesa Kontinen | |||||||||||||
Full Title: Topical anaesthesia for postoperative pain in adult patients undergoing tonsillectomy | |||||||||||||
Medical condition: Adult patients undergoing tonsillectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019591-67 | Sponsor Protocol Number: 1008032 | Start Date*: 2010-06-01 | |||||||||||
Sponsor Name:CHU de SAINT-ETIENNE | |||||||||||||
Full Title: Pain assessment during general anesthesia : DOLANS Study | |||||||||||||
Medical condition: perioperative analgesia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000202-29 | Sponsor Protocol Number: 2CA_2019_ORL_01 | Start Date*: 2020-07-27 | |||||||||||
Sponsor Name: Centro Clínico Académico - Braga, Associação (2CA-Braga) | |||||||||||||
Full Title: Single-center, double-blind, placebo-controlled study evaluating the efficacy of pre-incisional local analgesia with ropivacaine and dexamethasone for pain management after tonsillectomy | |||||||||||||
Medical condition: Patients selected for tonsillectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001088-11 | Sponsor Protocol Number: s56489 | Start Date*: 2014-07-29 |
Sponsor Name:MEDA | ||
Full Title: Academic study on the effects of MP 29-02 nasal spray on inflammatory mediators in allergic rhinitis | ||
Medical condition: Allergic rhinitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004540-29 | Sponsor Protocol Number: malin2.0 | Start Date*: 2013-05-24 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Injection treatment of ranula with OK 432 - A prospective, randomized, placebo controlled, double-blind study | ||
Medical condition: Patients with ranula. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003640-24 | Sponsor Protocol Number: C4221023 | Start Date*: 2023-01-16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005122-33 | Sponsor Protocol Number: NIMOBET-1 | Start Date*: 2014-03-04 | |||||||||||
Sponsor Name:MDM S.p.A. | |||||||||||||
Full Title: A phase II, randomized, double-blind, parallel groups study to assess the efficacy and safety of Nimodipine 20 mg + Betahistine 16 mg versus Placebo + Betahistine 16 mg in the treatment of vertigo | |||||||||||||
Medical condition: Vertigo | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005813-23 | Sponsor Protocol Number: GPD-1116/E2-A | Start Date*: 2008-12-24 | |||||||||||
Sponsor Name:ASKA Pharmaceutical.Co., Ltd | |||||||||||||
Full Title: Phase IIa study to evaluate the effects of GPD-1116 on late phase asthmatic response to allergen challenge in asthmatic patients. | |||||||||||||
Medical condition: Asthma response to allergen challenge | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004664-58 | Sponsor Protocol Number: BESTCILIA-WP5 | Start Date*: 2014-08-26 | |||||||||||
Sponsor Name:Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark | |||||||||||||
Full Title: RANDOMIZED CONTROLLED TRIAL (RCT) TO DETERMINE THE EFFICACY AND SAFETY OF AZITHROMYCIN (AZN) MAINTENANCE THERAPY FOR 6 MONTHS IN SUBJECTS WITH PCD - A DOUBLE-BLIND, PARALLEL GROUP STUDY | |||||||||||||
Medical condition: Primary ciliary dyskinesia (PCD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
